Continuous regional arterial infusion therapy with gabexate mesilate for severe acute pancreatitis

Figure 1 Changes in clinical parameters. The duration of abdominal pain (A) and of systemic inflammatory response syndrome (SIRS) (B) as well as the length of hospitalization (C) were investigated. Grey columns represent data for continuous regional arterial infusion using gabexate mesilate with antibiotics (CRAI-group) and white columns for non-CRAI group. Values are expressed as mean ± SE.

Figure 2 Changes in serum inflammation-related parameters. The levels of serum pancreatic amylase (P-amylase) (A), the white blood counts (WBC) (B), C-reactive protein (CRP) (C, and IL-6/IL-10 ratio D) were examined on days 0 (onset of pancreatitis), 1, 3, 7, and 14. Straight lines give data for continuous regional arterial infusion using gabexate mesilate with antibiotics (CRAI-group) and dotted lines for non-CRAI group. Values are expressed as mean ± SE. No significant differences between the groups were observed.